What it's for (Indications)
- This fixed-dose combination medication, comprising an angiotensin II receptor blocker (ARB) and a thiazide diuretic (losartan potassium and hydrochlorothiazide, respectively), is primarily indicated for the treatment of essential hypertension.
- It is typically prescribed when monotherapy with either losartan potassium or hydrochlorothiazide is insufficient to adequately control blood pressure, or as initial therapy in patients who are likely to need multiple antihypertensive drugs to achieve their blood pressure goals.
- The synergistic action of these two agents helps to achieve greater blood pressure reduction than either component alone, thus reducing the risk of cardiovascular events associated with uncontrolled hypertension.
- This combination is particularly useful in patients who have not responded to monotherapy, offering a convenient once-daily dosing regimen that can improve patient adherence and overall treatment outcomes.
- Its use should be guided by a comprehensive cardiovascular risk assessment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of hydrochlorothiazide + losartan potassium must be individualized based on the patient's response, tolerance, and existing medical conditions. It is typically administered once daily, with or without food. The usual starting dose and maintenance dose vary depending on the specific strengths available and the patient's prior antihypertensive regimen. Patients already on a diuretic, or those who are volume-depleted, may experience symptomatic hypotension following initiation; therefore, close monitoring and appropriate fluid repletion are essential before starting treatment. Dosage adjustments should be made cautiously, usually after several weeks to allow for the full therapeutic effect to be observed. Renal function, electrolyte balance, and overall cardiovascular status should be assessed prior to and periodically during treatment to ensure safe and effective dosing. It is crucial not to exceed the maximum recommended daily dose for either component, and dose titration should be performed under medical supervision. |
Safety & Warnings
Common Side Effects
- Common side effects associated with hydrochlorothiazide + losartan potassium include dizziness, fatigue, and upper respiratory tract infection.
- Less frequently, patients may experience dose-related orthostatic hypotension, particularly upon initiation of therapy.
- Due to the hydrochlorothiazide component, electrolyte imbalances such as hypokalemia, hyponatremia, and hypomagnesemia, as well as hypercalcemia, can occur and require careful monitoring.
- Other potential adverse effects related to the diuretic include hyperuricemia (which can precipitate gout), hyperglycemia, and hyperlipidemia.
- Less common but serious side effects may include angioedema (though rare with ARBs compared to ACE inhibitors), renal dysfunction (especially in patients with pre-existing renal impairment or renal artery stenosis), hepatic impairment, and blood dyscrasias (e.
- g.
- , thrombocytopenia, agranulocytosis).
- Patients should be advised to report any persistent or severe adverse reactions, such as unexplained muscle weakness, severe thirst, or unusual bruising, promptly to their healthcare provider for appropriate evaluation and management.
- Regular monitoring of blood pressure, kidney function, and electrolytes is important to detect and manage potential side effects early.
Serious Warnings
- Black Box Warning: **FETAL TOXICITY:** Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, hydrochlorothiazide + losartan potassium should be discontinued as soon as possible. There is no adequate data on the use of losartan or hydrochlorothiazide alone or in combination in pregnant women to inform any drug-associated risks. However, based on animal data and human mechanistic data, the use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy can cause fetal renal dysfunction, which can result in oligohydramnios and fetal death. Oligohydramnios, in turn, can be associated with fetal lung hypoplasia and skeletal deformations. Neonates with a history of in utero exposure to ARBs should be closely observed for hypotension, oliguria, and hyperkalemia. If this combination product is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Post-marketing experience with other angiotensin II receptor blockers indicates that if an ARB is used during pregnancy and oligohydramnios is identified, the drug should be discontinued as soon as possible, and appropriate fetal monitoring should be instituted.
- Patients receiving hydrochlorothiazide + losartan potassium should be routinely monitored for several important safety concerns.
- Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with an ARB, ACE inhibitor, or direct renin inhibitor (e.
- g.
- , aliskiren) is generally not recommended due to increased risks of hypotension, hyperkalemia, and changes in renal function, particularly in patients with pre-existing renal impairment or diabetes.
- Close monitoring is essential if such co-administration is deemed absolutely necessary.
- This combination can cause symptomatic hypotension, especially in volume-depleted patients (e.
- g.
- , those on high-dose diuretics, undergoing dialysis, or with severe heart failure).
- Hydrochlorothiazide can exacerbate or activate systemic lupus erythematosus and may increase the risk of non-melanoma skin cancer (basal cell and squamous cell carcinoma) with prolonged use; patients should be advised to limit sun exposure and undergo regular skin examinations.
- Caution is advised in patients with severe aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy, as ARBs may reduce cardiac output in these conditions.
- Patients with hepatic impairment may require dosage adjustments due to reduced metabolism of losartan.
How it Works (Mechanism of Action)
The therapeutic efficacy of hydrochlorothiazide + losartan potassium stems from the complementary actions of its two components, targeting different pathways involved in blood pressure regulation. Losartan potassium, an angiotensin II receptor blocker (ARB), selectively blocks the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle, the adrenal glands, and the kidneys. This blockade inhibits the potent vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, reduced sodium and water reabsorption, and consequently, a decrease in systemic vascular resistance and blood pressure. Hydrochlorothiazide, a thiazide diuretic, acts primarily in the cortical diluting segment of the renal tubule, where it inhibits the reabsorption of sodium and chloride ions from the luminal membrane, likely by interfering with the Na+-Cl- cotransporter. This inhibition increases the excretion of sodium, chloride, and water, thereby reducing plasma volume, and indirectly contributes to a reduction in peripheral vascular resistance. The combined effect of these two distinct mechanisms results in a more potent and sustained antihypertensive action than either agent alone, achieving optimal blood pressure control by addressing both fluid volume and vascular tone.